Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
Lenders, J. W. M., Pacak, K., Walther, M. M., Linehan, W. M., Mannelli, M., Friberg, P., Keiser, H. R., Goldstein, D. S., & Eisenhofer, G. (2002) · JAMA · doi:10.1001/jama.287.11.1427 · Cited by 1,134
Molecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors
Fallah, J., Brave, M. H., Weinstock, C., Mehta, G. U., Bradford, D., Gittleman, H., Bloomquist, E. W., Charlab, R., Hamed, S. S., Miller, C. P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1054 · Cited by 180 · cited 1×
“Specifically, on August 13, 2021, the U.S. Food and Drug Administration (FDA) approved Belzitufan for the treatment of renal cell carcinoma, CNS hemangioblastomas, and pancreatic neuroendocrine tumors associated with VHL disease [68].”
The VHL tumor suppressor: master regulator of HIF
Haase, V. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649394 · Cited by 175
The VHL tumor suppressor and HIF: insights from genetic studies in mice
Kapitsinou, P. P., & Haase, V. H. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402313 · Cited by 151
Von Hippel-Lindau Disease: Current Challenges and Future Prospects
Gläsker, S., Vergauwen, E., Koch, C. A., Kutikov, A., & Vortmeyer, A. O. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s190753 · Cited by 99
Research works printed but not linked: 61
- Chittiboina P, Lonser RR (2015) Von Hippel-Lindau disease. Handbook of clinical neurology. pp. 139–156 · DOI · Paper page
- Leeuwaarde AS, van Nesselrooij B (2024) Von Hippel-Lindau syndrome. GeneReviews, s.l.
- Devarajan P, De Leon M, Talasazan F, Schoenfeld AR, Davidowitz EJ, Burk RD (2001) The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. J Biol Chem pp. 40599–40605 · DOI
- Ohh M, Taber CC, Ferens FG, Tarade D (2022) Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata. eLife p. e80774 · DOI
- Choueiri. TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S (2013) The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin cancer Research: Official J Am Association Cancer Res pp. 5218–5226 · DOI
- Peng S, Zhang J, Tan X, Huang Y, Xu J, Silk N, Zhang D, Liu Q, Jiang J (2020) The VHL/HIF Axis in the development and treatment of pheochromocytoma/paraganglioma. Front Endocrinol · DOI
- Schmid S, Gillessen S, Binet I, Brändle M, Engeler D, Greiner J, Hader C, Heinimann K, Kloos P, Krek W, Krull I, Stoeckli SJ, Sulz MC, van Leyen K, Weber J, Rothermundt C, Hundsberger T (2014) Management of von hippel-lindau disease: an interdisciplinary review. Oncol Res Treat pp. 761–771 · DOI
- Kim (2018) Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. Frontiers in pediatrics. · DOI
- van Leeuwaarde, Ahmad S, van Nesselrooij B et al (2000) Von Hippel-Lindau syndrome. GeneReviews® [Internet], s.l.
- del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, Olmos G, Landazuri MO (2003) The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem pp. 48690–48695 · DOI · Paper page
- Zhang J, Zhang Q (2018) VHL and hypoxia signaling: beyond HIF in Cancer. Biomedicines · DOI
- Ohh. M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell pp. 959–968 · DOI · Paper page
- Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG Jr, Ohh M (2004) pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol pp. 3251–3261 · DOI · Paper page
- Roe JS, Youn HD The positive regulation of p53 by the tumor suppressor VHL. Cell cycle (Georgetown, Tex.). 2006, pp. 2054–2056 · DOI
- Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W (2003) Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol pp. 64–70 · DOI · Paper page
- Klingler JH, Gläsker S, Bausch B, Urbach H, Krauss T, Jilg CA, Steiert C, Puzik A, Neumann-Haefelin E, Kotsis F, Agostini H, Neumann HPH, Beck J (2020) Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Child’s Nerv Syst pp. 2537–2552 · doi:10.1007/s00381-020-04712-5
- Dollfus H, Massin P, Taupin P, Nemeth C, Amara S, Giraud S, Béroud C, Dureau P, Gaudric A, Landais P, Richard S (2002) Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Investig Ophthalmol Vis Sci pp. 3067–3074
- Wiley HE, Krivosic V, Gaudric A, Gorin MB, Shields C, Shields J, Aronow ME, Chew E (2019) Y. MANAGEMENT OF RETINAL HEMANGIOBLASTOMA IN VON HIPPEL-LINDAU DISEASE. Retina (Philadelphia, Pa.). pp. 2254–2263 · DOI
- Castro-Teles J, Sousa-Pinto B, Rebelo S, Pignatelli D (2021) Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack. Endocr Connections pp. R293–R304 · DOI
- Frederik JWM, Höppener, Cornelis JM (2003) Lips. Pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metabolism pp. 969–974 · DOI
- Kantorovich V, Pacak K (2010) Pheochromocytoma and paraganglioma. Prog Brain Res pp. 343–373 · DOI
- Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S (2019) Treatment options for pancreatic neuroendocrine tumors. Cancers · DOI
- Hackert T, Büchler MW, Werner J (2011) Current state of surgical management of pancreatic cancer. Cancers pp. 1253–1273 · DOI
- Kim (2005) Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg pp. 503–512 · doi:10.3171/jns.2005.102.3.0503
- Choyke PL, Glenn GM, Wagner JP, Lubensky IA, Thakore K, Zbar B, Linehan WM, Walther MM (1997) Epididymal cystadenomas in von Hippel-Lindau disease. Urology pp. 926–931 · DOI
- Haase (2006) The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int pp. 1302–1307 · DOI · Paper page
- Na X, Wu G, Ryan CK, Schoen SR, di’Santagnese PA, Messing EM (2003) Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol pp. 588–592 · DOI · Paper page
- Kim., Zschiedrich S (2018) Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. Frontiers in pediatrics. · DOI
- Pastore AL, Palleschi G, Silvestri L, Moschese D, Ricci S, Petrozza V, Carbone A, Di Carlo A (2015) Serum and urine biomarkers for human renal cell carcinoma. Dis Markers · DOI
- Zhu W, Zheng G, Yan X, Liu M, Li X, Cheng Y, Bai C, Zhang Y, Huo L (2024) Diagnostic efficacy of [68Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging pp. 4127–4133 · doi:10.1007/s00259-024-06801-y
- Friedrich (1999) Von Hippel-Lindau syndrome. A pleomorphic condition. Cancer pp. 2478–2482 · DOI · Paper page
- Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, Nathanson KL, States LJ, Tomlinson GE, Villani A, Voss SD, Schiffman JD, Wasserman JD (2017) Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin cancer Research: Official J Am Association Cancer Res pp. e68–e75 · DOI · Paper page
- Hudler P, Urbancic M (2022) The role of VHL in the development of von Hippel-Lindau disease and erythrocytosis. Genes · DOI
- Casey RT, Warren AY, Martin JE, Challis BG, Rattenberry E, Whitworth J, Andrews KA, Roberts T, Clark GR, West H, Smith PS, Docquier FM, Rodger F, Murray V, Simpson HL, Wallis Y, Giger O, Tran M (2017) Tomkin. Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. The Journal of clinical endocrinology and metabolism. pp. 4013–4022 · DOI
- Garg MK, Kharb S, Brar KS, Gundgurthi A, Mittal R (2011) Medical management of pheochromocytoma: role of the endocrinologist. Indian J Endocrinol Metabol pp. S329–S336 · DOI
- Václavík J, Stejskal D, Lacnák B, Lazárová M, Jedelský L, Kadalová L, Janosová M, Frysák Z, Vlcek P (2007) Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens pp. 1427–1431 · DOI · Paper page
- Bílek R, Vlček P, Šafařík L, Michalský D, Novák K, Dušková J, Václavíková E, Widimský J, Jr, Zelinka T (2019) Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers. · DOI
- Carrasquillo JA, Chen CC, Jha A, Ling A, Lin FI, Pryma DA, Pacak K (2021) Imaging of pheochromocytoma and paraganglioma. J Nuclear Medicine: Official Publication Soc Nuclear Med pp. 1033–1042 · DOI
- Timmers HJLM, Taïeb D, Pacak K, Lenders J (2024) W. M. Imaging of pheochromocytomas and paragangliomas. Endocr Rev pp. 414–434 · DOI
- Pacak K (2007) Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab pp. 4069–4079 · DOI · Paper page
- Ramachandran R, Rewari V (2017) Current perioperative management of pheochromocytomas. Indian J Urology: IJU: J Urol Soc India pp. 19–25 · DOI
- Öberg K (2018) Management of functional neuroendocrine tumors of the pancreas. Gland surgery. pp. 20–27 · DOI
- Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, Kebebew E (2018) Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with von Hippel-Lindau disease. JAMA Oncol. pp. 124–126 · DOI
- Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA (2020) & P. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. pp. 1–33 · DOI · Paper page
- Lee A, Chan DL, Wong MH, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N (2017) Systematic review of the role of targeted therapy in metastatic neuroendocrine tumors. Neuroendocrinology pp. 209–222 · doi:10.1159/000446115
- Hong B, Ma K, Zhou J, Zhang J, Wang J, Liu S, Zhang Z, Cai L, Zhang N, Gong K (2019) Frequent mutations of VHL gene and the clinical phenotypes in the largest Chinese cohort with von Hippel-Lindau disease. Front Genet · doi:10.3389/fgene.2019.00867
- Zanoletti E, Girasoli L, Borsetto D, Opocher G, Mazzoni A, Martini A (2017) Endolymphatic sac tumour in von Hippel-Lindau disease: management strategies. Acta otorhinolaryngologica Italica: organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale. pp. 423–429 · doi:10.14639/0392-100x-1402
- Offergeld C, Brase C, Yaremchuk S, Mader I, Rischke HC, Gläsker S, Schmid KW, Wiech T, Preuss SF, Suárez C, Kopeć T, Patocs A, Wohllk N, Malekpour M, Boedeker CC, Neumann HP (2012) Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo, Brazil). pp. 19–28 · DOI · Paper page
- Kaelin (2022) Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Investig p. e162480 · DOI · Paper page
- Else T, Wong KK, Frey KA, Brooks AF, Viglianti BL, Raffel DM (2024) 3-[18F]Fluoro-para-hydroxyphenethylguanidine (3-[18F]pHPG) PET-A novel imaging modality for paraganglioma. J Endocr Soc · DOI
- Fang F, Ding L, He Q, Liu M (2020) Preoperative Management of Pheochromocytoma and Paraganglioma. Frontiers in endocrinology. · DOI
- Mehta GU, Shively SB, Gläsker S, Bechert CJ, Zhuang Z, Raffeld M, Lonser RR, Oldfield EH, Vortmeyer AO (2007) Von Hippel-Lindau disease: epididymal cystadenoma targeted by metastatic events. Urology · doi:10.1016/j.urology.2007.03.047
- Odrzywolski KJ, Mukhopadhyay S (2010) Papillary cystadenoma of the epididymis. Arch Pathol Lab Med pp. 630–633 · DOI
- Papadakis GZ, Millo C, Sadowski SM, Bagci U, Patronas NJ (2016) Epididymal cystadenomas in von Hippel-Lindau disease showing increased activity on 68Ga DOTATATE PET/CT. Clin Nucl Med pp. 781–782 · DOI
- Lehmann H, Vicari D, Wild PJ, Frew IJ (2015) Combined deletion of Vhl and Kif3a accelerates renal cyst formation. J Am Soc Nephrology: JASN pp. 2778–2788 · DOI
- van Asselt SJ, de Vries EG, van Dullemen HM, Brouwers AH, Walenkamp AM, Giles RH, Links TP (2013) Pancreatic cyst development: insights from von Hippel-Lindau disease. Cilia · DOI
- Ayloo S, Molinari M (2016) Pancreatic manifestations in von Hippel-Lindau disease: A case report. Int J Surg Case Rep pp. 70–72 · doi:10.1016/j.ijscr.2016.02.031
- Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A (2022) & Pancreatic manifestations recommendations development subcommittee of the VHL alliance. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Cancer pp. 435–446 · DOI · Paper page
- Slater A, Moore NR, Huson SM (2003) The natural history of cerebellar hemangioblastomas in von Hippel-Lindau disease. AJNR Am J Neuroradiol pp. 1570–1574
- Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Höfler H, Latif F, Lerman MI, Zbar B, Neumann HP (1995) Von Hippel-Lindau (VHL) disease with pheochromocytoma in the black forest region of Germany: evidence for a founder effect. Hum Genet pp. 551–556 · DOI · Paper page
- Liu P, Zhu F, Li M, Dube DA, Liu Q, Wang C, Xiao Q, Zhang L, Gao S, Li Z, Zhang B, Liu J, Liu L, Chen X (2019) Von Hippel-Lindau black forest mutation inherited in a large Chinese family. Gland Surg pp. 343–353 · doi:10.21037/gs.2019.08.03
Metadata
- Authors
- Harbi, E., & Aschner, M.
- Venue
- Molecular Biology Reports
- Published
- 2025-03-05
- Volume
- 52
- Issue
- 1
- ISSN
- 0301-4851
- 1573-4978
- Cited by
- 18
- References
- 7
- Language
- en
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.